ERBB2 and gastric cancer: Trastuzumab, one of the most effective anti-HER2 antibodies for breast and gastric cancers, has been used in clinical therapy for a long time; however, the emergence of resistance is a significant barrier to trastuzumab-based treatment for HER2-overexpressing breast and gastric cancers.